PMID- 24712861
OWN - NLM
STAT- MEDLINE
DCOM- 20141215
LR  - 20181202
IS  - 1743-7563 (Electronic)
IS  - 1743-7555 (Linking)
VI  - 10 Suppl S3
DP  - 2014 Apr
TI  - The use of vemurafenib in Australian patients with unresectable or metastatic 
      melanoma containing the V600 BRAF gene mutation.
PG  - 1-15
LID - 10.1111/ajco.12200 [doi]
AB  - Metastatic melanoma remains one of the major causes of death related to skin 
      cancers and has been resistant to traditional anticancer therapies. The clinical 
      development of vemurafenib in the treatment of metastatic melanoma with the V600 
      mutation of the BRAF gene has provided meaningful improvements in the overall 
      survival and progression-free survival of metastatic melanoma patients. However, 
      significant side effects have been noted with this therapy, in particular 
      cutaneous adverse events (AEs) such as rashes, squamous cell carcinoma and severe 
      photosensitivity to UVA light among others. With an emphasis on the Australian 
      perspective, this review provides an overview of the clinical development of 
      vemurafenib, its attendant dose-limiting toxicities and other AEs, 
      recommendations for safety monitoring, supportive treatments of AEs and dose 
      modifications, with the aim of maximizing the chances of continuing beneficial 
      treatment.
CI  - (c) 2014 Wiley Publishing Asia Pty Ltd.
FAU - Brown, Michael P
AU  - Brown MP
AD  - Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, 
      Australia.
FAU - Long, Georgina V
AU  - Long GV
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Australia
TA  - Asia Pac J Clin Oncol
JT  - Asia-Pacific journal of clinical oncology
JID - 101241430
RN  - 0 (Indoles)
RN  - 0 (Sulfonamides)
RN  - 207SMY3FQT (Vemurafenib)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
SB  - IM
MH  - Australia
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Indoles/adverse effects/*therapeutic use
MH  - Melanoma/*drug therapy/*genetics
MH  - *Mutation
MH  - Neoplasm Metastasis
MH  - Proto-Oncogene Proteins B-raf/antagonists & inhibitors/*genetics
MH  - Sulfonamides/adverse effects/*therapeutic use
MH  - Treatment Outcome
MH  - Vemurafenib
OTO - NOTNLM
OT  - Zelboraf
OT  - adverse drug reaction
OT  - drug
OT  - malignant melanoma
OT  - toxicity
OT  - vemurafenib
EDAT- 2014/04/10 06:00
MHDA- 2014/12/17 06:00
CRDT- 2014/04/10 06:00
PHST- 2014/03/17 00:00 [accepted]
PHST- 2014/04/10 06:00 [entrez]
PHST- 2014/04/10 06:00 [pubmed]
PHST- 2014/12/17 06:00 [medline]
AID - 10.1111/ajco.12200 [doi]
PST - ppublish
SO  - Asia Pac J Clin Oncol. 2014 Apr;10 Suppl S3:1-15. doi: 10.1111/ajco.12200.